Company intelligence / Profile preview
ProGenis Pharmaceuticals
Perth, Western Australia, Australiaprogenispharma.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
A promising TMO drug for type 2 diabetes is currently in preclinical developmental stage, while another is entering preclinical developmental phase for multiple sclerosis and Duchenne muscular dystrophy[4]
- Therapeutic areas
- EndocrinologyRare DiseasesNeurology
- Modalities
- RNA therapeuticsantisense oligonucleotides (ASOs)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Murdoch UniversityPerron Institute
Beyond the preview
Go deeper on ProGenis Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ProGenis Pharmaceuticals.